Product Description: Afizagabar (S44819) is a first-in-class, competitive, and selective antagonist at the GABA-binding site of the α5-GABAAR, with an IC50 of 585 nM for α5β2γ2 and a Ki of 66 nM for α5β3γ2. Afizagabar enhances hippocampal synaptic plasticity and exhibits pro-cognitive efficacy[1].
Applications: Neuroscience-Neuromodulation
Formula: C19H12FN3O2S
References: [1]Etherington LA, et al. Selective inhibition of extra-synaptic α5-GABAA receptors by S44819, a new therapeutic agent. Neuropharmacology. 2017;125:353-364.
CAS Number: 1398496-82-6
Molecular Weight: 365.38
Compound Purity: 98.40
Research Area: Neurological Disease
Solubility: DMSO : 6.25 mg/mL (ultrasonic)
Target: GABA Receptor